Nurix Therapeutics reported its first‑quarter 2026 financial results, posting a net loss of $87.2 million, or $0.79 per share, compared with a $56.4 million loss ($0.67 per share) in the same period a year earlier. The company’s revenue fell to $6.3 million from $18.5 million in Q1 2025, reflecting a strategic shift toward clinical development rather than product sales.
Cash and cash equivalents stood at $540.7 million as of February 28 2026, down from $592.9 million at the end of 2025. The balance is projected to support operations for the next 18 to 24 months, given the company’s current burn rate.
Research and development expenses rose to $264.5 million in Q1 2026 from $194.8 million in Q1 2025, driven largely by the bexobrutideg program. The company continues to enroll patients in the DAYBreak CLL‑201 Phase 2 trial of bexobrutideg and reports progress on its STAT6 degrader and CBL‑B inhibitor NX‑1607.
The results are typical for a late‑stage biopharma focused on clinical milestones. Investors will view the cash balance and ongoing clinical progress as key indicators of Nurix’s near‑term financial resilience and long‑term upside potential.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.